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Appendix Table 1 Instances of STOPP potentially inappropriate prescribing (PIP) 
Criteria 
All Exc. prns 
Cardiovascular System   
Loop diuretic for dependent ankle oedema only i.e. no clinical signs 
of heart failure 
8 8 
Loop diuretic first line for hypertension  34 34 
Use of diltiazem or verapamil with NYHA Class III or IV heart 
failure 
2 2 
Calcium channel blockers and constipation  24 24 
Aspirin and history of peptic ulcer disease without H2 
antagonist/PPI  
1 1 
Aspirin without an indication  20 20 
Warfarin for first, uncomplicated deep venous thrombosis for longer 
than 6 months duration 
1 1 
Central nervous system   
TCA and dementia 8 8 
TCA and glaucoma  3 3 
TCAs and cardiac conductive abnormalities 2 2 
TCAs and constipation  12 12 
Criteria 
All Exc. prns 
TCAs and opiate or calcium blockers  20 13 
TCA and urinary retention  1 1 
Long term long acting benzodiazepine or benzodiazepines with long 
acting metabolites  
61 61 
Long-term (i.e. > 1 month) neuroleptics as long-term hypnotics 22 22 
Long-term neuroleptics ( > 1 month) in those with Parkinsons’ 
disease 
25 25 
Phenothiazines in patients with epilepsy 5 0 
Anticholinergics to treat extra-pyramidal side-effects of neuroleptic 
medications 
14 14 
Selective serotonin re-uptake inhibitors (SSRI’s) with a history of 
clinically significant hyponatraemia (non-iatrogenic 
hyponatraemia<130mmol/l within the previous 2 months). 
4 4 
>1 week first-generation antihistamines  25 25 
Gastrointestinal system   
Diphenoxylate, loperamide or codeine phosphate for treatment of 
diarrhoea of unknown cause 
1 1 
Prochlorperazine or metoclopramide with Parkinsons disease 4 2 
PPI for peptic ulcer disease at full therapeutic dosage for >8 weeks  166 166 
Criteria 
All Exc. prns 
Anticholinergic antispasmodic drugs with chronic constipation 5 0 
Respiratory system   
Theophylline as monotherapy for COPD 2 2 
Nebulised ipratropium with glaucoma 4 3 
Musculoskeletal system   
NSAIDs and hypertension  60 26 
NSAIDs and heart failure 12 2 
Long-term continuous NSAIDs for osteoarthritis  6 6 
Warfarin and NSAIDs together 9 4 
NSAID with chronic renal failure  4 1 
Long-term corticosteroids (>3 months) as monotherapy for 
rheumatoid arthrtitis or osterarthritis 
8 8 
Urogenital System   
Bladder antimuscarinic drugs with dementia 12 12 
Antimuscarinic drugs with chronic glaucoma 2 2 
Antimuscarinic drugs with chronic constipation 17 17 
Antimuscarinic drugs with chronic prostatism 3 3 
Criteria 
All Exc. prns 
Alpha-blockers in males with frequent incontinence 12 12 
Alpha-blockers with long-term urinary catheter in situ 3 3 
Drugs that adversely affect fallers   
Benzodiazepines in individuals with a history of recurrent falls 197 115 
Neuroleptic drugs in individuals with a history of recurrent falls 138 115 
First generation antihistamines in individuals with a history of 
recurrent falls 
24 16 
Long-term opiates in individuals with a history of recurrent falls 71 71 
Analgesic Drugs   
Use of long-term powerful opiates e.g. morphine or fentanyl as first 
line therapy for mild-moderate pain 
4 4 
Long-term opiates in those with dementia unless indicted for 
palliative care or management of moderate/severe chronic pain 
syndrome 
22 22 
Duplicate class 202 62 
Total STOPP PIP instances 1280 955 
Key: Exc: Excluding; prn: Pro Re Nata (as needed/ as required); NYHA: New York Heart Association; 
H2 receptor antagonist: Histamine 2 receptor antagonist; PPI: Proton Pump Inhibitor; SSRIs: 
Selective Serotonin Reuptake Inhibitors; COPD: Chronic Obstructive Pulmonary Disease; NSAIDs: 
Non-Steroidal Anti-Inflammatory Drugs; STOPP: Screening Tool of Older People’s potentially 
inappropriate Prescriptions; PIP: Potentially Inappropriate Prescribing. 
Appendix Table 2 Instances of Beers’ ID potentially inappropriate prescribing (PIP) 
Criteria All Exc. prns 
Muscle relaxants and antispasmodics:oxybutynin (do not consider 
extended release oxybutynin) 
10 10 
Flurazepam 15 15 
Amitriptyline, chlordiazepoxide- amitriptyline and perphenazine- 
amitriptyline 
20 20 
Doxepin 1 1 
Doses of short acting benzodiazepines: doses greater than 
lorazepam 3mg; oxazepam 60mg; alprazolam 2mg; temazepam 
15mg; triazolam0.25mg. 
10 10 
Chlordiazepoxide, chlordiazepoxide- amitriptyline, clidinium-
chlordiazepoxide, diazepam, quazepam, halazepam and 
chlorazepate 
70 41 
Long-acting benzodiazepines 7 6 
Gastrointestinal antispasmodic drugs:dicyclomide, hyoscyamine, 
propantheline, belladonna alkoloids and clinidium-chlordiazepoxide 
27 8 
Anticholinergics and anthistamines: Chlorpheniramine, 
diphenhydramine, hydroxyzine, cyproheptadine, promethazine, 
tripelennamine and dexchlorpheniramine 
25 12 
Criteria All Exc. prns 
Daily fluoxetine 17 17 
Amiodarone 15 15 
Nitrofurantoin 13 13 
Doxazosin 9 9 
Oestrogen 1 1 
Total Beers ID PIP Instances 240 178 
Key: Exc: Excluding; prn: Pro Re Nata (as needed/ as required); ID: Independent of Diagnosis; PIP: 
Potentially Inappropriate Prescribing. 
 
  
Appendix Table 3 Instances of Beers’ CD potentially inappropriate prescribing (PIP) 
Criteria All Exc. prns 
Gastric of duodenal ulcers AND NSAIDs and aspirin 9 4 
Seizures or epilepsy AND Clozapine, chlorpromazine, thioridazine 
and thiothixene 
1 0 
Blood clotting disorders or receiving anticoagulant therapy AND 
aspirin, NSAIDs, dipryidamole, ticlodipine and clopidogrel 
10 7 
Bladder outflow obstruction AND anticholinergics and 
antihistamines, GI antispasmodic drugs, muscle relaxants, 
oxybutynin, flavoxate, anticholinergics, antidepressants, 
decongestants and tolteridine. 
34 29 
Stress incontinence AND α-blockers, anticholinergics, tricyclic 
antidepressants (imipramine hydrochloride, doxepin hydrochloride 
and amitriptyline hydrochloride) and long-acting benzodiazepines. 
77 58 
Arrhythmias AND Tricyclic antidepressants (imipramine 
hydrochloride, doxepin hydrochloride and amitriptyline 
hydrochloride) 
1 1 
Parkinson disease AND Metoclopramide, conventional 
antipsychotics and tacrine 
5 3 
Cognitive impairment AND barbiturates, anticholinergics, 
antispasmodics, muscle relaxants and cns stimulants: 
68 49 
Criteria All Exc. prns 
dextroamphetamine, methylphenidate, methamphetamine and 
pemolin. 
Depression AND long-term benzodiazepine use. sympatholytic 
agents: methyldopa, reserpine and guanethidine 
87 87 
Syncope or falls AND short to intermediate acting benzodiazepine 
and tricyclic antidepressants (imipramine hydrochloride, doxepin 
hydrochloride and amitriptyline hydrochloride) 
208 124 
SIADH/hyponatraemia AND SSRIs (fluoxetine, citalopram, 
fluvoxamine, paroxetine and Sertraline) 
2 2 
Obesity AND Olanzapine 1 1 
COPD AND Long-acting benzodiazepines: chlordiazepoxide, 
chlordiazepoxide- amitriptyline, clidinium-chlordiazepoxide, 
diazepam, quazepam, halazepam and chlorazepate. ß-blockers: 
propranolol. 
7 4 
Constipation AND calcium channel blockers, anticholinergics, 
tricyclic antidepressants (imipramine hydrochloride, doxepin 
hydrochloride and amitriptyline hydrochloride) 
81 70 
Total Beers CD PIP Instances 591 439 
Key: Exc: Excluding; prn: Pro Re Nata (as needed/ as required); GI: Gastro-Intestinal; SIADH: 
Syndrome of Inappropriate Anti-Diuretic Hormone; SSRIs: Selective Serotonin Reuptake Inhibitors; 
COPD: Chronic Obstructive Pulmonary Disease; NSAIDs: Non-Steroidal Anti-Inflammatory Drugs; CD: 
Considering Diagnosis; PIP: Potentially Inappropriate Prescribing. 
